ReviewArchives of microbiology2025
Insights for napyradiomycin family: structures, bioactivities and biosynthetic pathways.
Review in Archives of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Napyradiomycins (NPDs), a family of structurally diverse terpenoids isolated from Streptomyces, have attracted significant scientific interest due to their unique halogenation patterns and potent bioactivities. Since identifying the first member from Streptomyces in 1986, over 50 NPDs have been characterized, demonstrating remarkable efficacy against drug-resistant bacteria and cancer cells, making them promising candidates for novel drug development. In this review, we provided an in-depth exploration of the complex chemical structure of NPDs, their diverse bioactivities, and the biosynthetic pathways involved in their formation. In particular, we collectively concluded the structure-activity relationship data to highlight the importance of the molecular features of napyradiomycins determining their therapeutic potential. Recent discoveries have shed light on the unique role of halogenases, which contribute to the structural diversity and enhance the biological potency of napyradiomycins, thus refining the known biosynthetic pathways. The data presented here aims to stimulate further research and facilitate the advancement of NPDs toward becoming first-line therapies for infectious diseases and cancer.
Indexed as
Identifiers
40080144What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.